Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-02T21:35:47.011Z.
Calculation as of: 2026-10-02T21:35:47.011Z.
Quote observation: 2026-10-02T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 054a65786064a73545931b308e74131b250e2c5f6c2462854f5738f681d07736
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-08-13.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$63.32B
EV/EBITDA Ratio
13.01x
TTM Avg
22.71x
3Y Avg
31.07x
5Y Avg
28.80x
Market Cap
$53.47B
EV/EBITDA Ratio
16.41x
TTM Avg
16.91x
3Y Avg
15.68x
5Y Avg
30.06x
Market Cap
$49.03B
EV/EBITDA Ratio
23.47x
TTM Avg
26.01x
3Y Avg
26.99x
5Y Avg
29.15x
Market Cap
$48.72B
EV/EBITDA Ratio
11.77x
TTM Avg
12.48x
3Y Avg
14.16x
5Y Avg
14.86x
Market Cap
$47.38B
EV/EBITDA Ratio
25.96x
TTM Avg
22.53x
3Y Avg
23.15x
5Y Avg
23.28x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Natera, Inc. (NTRA) | $58.77B | N/A | N/A | N/A | N/A |
| Cencora, Inc. (COR)vs › | $60.13B | 12.82x | 14.25x | 13.62x | 12.30x |
| Boston Scientific Corporation (BSX)vs › | $63.32B | 13.01x | 22.71x | 31.07x | 28.80x |
| Cardinal Health, Inc. (CAH)vs › | $53.47B | 16.41x | 16.91x | 15.68x | 30.06x |
| Edwards Lifesciences Corporation (EW)vs › | $49.03B | 23.47x | 26.01x | 26.99x | 29.15x |
| Becton, Dickinson and Company (BDX)vs › | $48.72B | 11.77x | 12.48x | 14.16x | 14.86x |
| Agilent Technologies, Inc. (A)vs › | $47.38B | 25.96x | 22.53x | 23.15x | 23.28x |
| Humana Inc. (HUM)vs › | $46.63B | 19.47x | 17.44x | 14.58x | 14.65x |
| Cigna Corporation (CI)vs › | $71.48B | 7.86x | 8.37x | 9.32x | 9.64x |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $46.04B | 19.94x | 17.39x | 196.26x | 159.23x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2015-08-13 | 86.99x |
| 2015-08-12 | 91.77x |
| 2015-08-11 | 93.70x |
| 2015-08-10 | 96.66x |
| 2015-08-07 | 96.06x |
| 2015-08-06 | 100.71x |
| 2015-08-05 | 98.66x |
| 2015-08-04 | 96.91x |
| 2015-08-03 | 94.85x |
| 2015-07-31 | 102.29x |
| 2015-07-30 | 102.53x |
| 2015-07-29 | 103.01x |
| 2015-07-28 | 101.98x |
| 2015-07-27 | 101.74x |
| 2015-07-24 | 109.12x |
| 2015-07-23 | 116.37x |
| 2015-07-22 | 118.49x |
| 2015-07-21 | 117.46x |
| 2015-07-20 | 122.48x |
| 2015-07-17 | 119.15x |
| 2015-07-16 | 125.20x |
| 2015-07-15 | 117.04x |
| 2015-07-14 | 117.94x |
| 2015-07-13 | 120.42x |
| 2015-07-10 | 124.41x |
| 2015-07-09 | 121.39x |
| 2015-07-08 | 122.72x |
| 2015-07-07 | 125.92x |
| 2015-07-06 | 125.92x |
| 2015-07-02 | 130.40x |
| 2015-07-01 | 101.74x |
